Compositions And Methods For Inhibiting Adhesions

• US 20080069857A1
• Filed: 04/12/2007
• Published: 03/20/2008
• Est. Priority Date: 04/12/2006
• Status: Abandoned Application

• Current Assignee: E. I. du Pont de Nemours and Company (Corteva, Inc.), Massachusetts Institute of Technology, The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Yeo, Yoon, Ito, Taichi, Kodokian, George, Langer, Robert, Kohane, Daniel
• Application Number:
  US11/734,537
• Publication Number:
  US 20080069857A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61L 31/041 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 31/129 containing macromolecular fillers
• CPC Class Codes: A61L 31/145 Hydrogels or hydrocolloids
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08J 2301/28 Alkyl ethers
• CPC Class Codes: C08J 2305/02 Dextran; Derivatives thereof
• CPC Class Codes: C08J 2305/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C08J 3/075 Macromolecular gels
• CPC Class Codes: C08J 3/246 Intercrosslinking of at least two polymers
• CPC Class Codes: C08L 1/28 Alkyl ethers
• CPC Class Codes: C08L 5/02 Dextran; Derivatives thereof
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Abstract

The present invention provides compositions and methods for inhibiting adhesions. The methods involve administering solutions containing hydrogel precursors such as polysaccharide derivatives, e.g., derivatives of hyaluronic acid, cellulose, or dextran, to a subject at a site where adhesions may form, e.g., as a consequence of surgery, injury, or infection. The hydrogel precursors, e.g., polysaccharide derivatives, become crosslinked following their administration to form a hydrogel that maintains tissue separation. In certain embodiments of the invention one or both solutions contains particles, e.g., polymeric nanoparticles or microparticles, so that a composite hydrogel containing the particles is formed. The solution(s), particle(s), or both, may contain a biologically active agent such as an agent that contributes to inhibiting adhesions. The biologically active agent may be covalently attached to a hydrogel precursor.

Claims

1. A method of inhibiting adhesions, the method comprising the steps of:

administering a first hydrogel precursor to a location within the body of a subject; and

administering a second hydrogel precursor to the location within the body of the subject,

wherein the first hydrogel precursor is a cellulose derivative or a dextran derivative;

wherein the second hydrogel precursor is a dextran derivative;

wherein the first and second hydrogel precursors become crosslinked to form a hydrogel following contact of the hydrogel precursors with one another; and

wherein the hydrogel inhibits adhesions.

2. The method of claim 1, wherein the first hydrogel precursor comprises a first functional group;

wherein the second hydrogel precursor comprises a second functional group; and

wherein the first and second functional groups react with one another to form a covalent bond under physiological conditions.

3. The method of claim 1, wherein at least one of the first hydrogel precursor or the second hydrogel precursor comprises a non-polysaccharide portion.

4. The method of claim 1, wherein the cellulose derivative is selected from the group consisting of MC derivatives, CMC derivatives, and HPMC derivatives.

5. The method of claim 1, wherein the first hydrogel precursor is a CMC derivative and the second hydrogel precursor is a carboxymethyl dextran derivative.

6. The method of claim 1, wherein the second hydrogel precursor is CMDX-ADH and the first hydrogel precursor is selected from the group consisting of MC—

CHO, CMC—

CHO, and HPMC—

CHO.

7. The method of claim 1, wherein the second hydrogel precursor is CMDX-ADH and the first hydrogel precursor is CMC—

CHO.

8. The method of claim 1, wherein the first hydrogel precursor is a first dextran derivative and the second hydrogel precursor is a second dextran derivative.

9. The method of claim 8, wherein the first dextran derivative is CMDX-ADH and the second dextran derivative is CMDX—

CHO.

10. The method of claim 1, wherein the hydrogel precursors are administered in solution.

11. The method of claim 1, wherein the hydrogel precursors are administered endoscopically or using a syringe.

12. The method of claim 1, wherein the hydrogel forms within between 1 and 100 seconds following contact of the hydrogel precursors with one another.

13. The method of claim 1, wherein the hydrogel precursors are administered substantially in the absence of a free crosslinking agent.

14. The method of claim 1, wherein the method comprises administering at least one solution comprising a cellulose derivative, wherein the concentration of the cellulose derivative is greater than 5 mg/ml.

15. The method of claim 1, wherein the method comprises administering at least one solution comprising a cellulose derivative, wherein the concentration of the cellulose derivative is greater than 25 mg/ml.

16. The method of claim 1, wherein the method comprises administering at least one solution comprising a cellulose derivative, wherein the concentration of the cellulose derivative is greater than 50 mg/ml.

17. The method of claim 1, wherein the method comprises administering at least one solution comprising a dextran derivative, wherein the concentration of the dextran derivative is greater than 5 mg/ml.

18. The method of claim 1, wherein the method comprises administering at least one solution comprising a dextran derivative, wherein the concentration of the dextran derivative is greater than 25 mg/ml.

19. The method of claim 1, wherein the method comprises administering at least one solution comprising a dextran derivative wherein the concentration of the dextran derivative is greater than 50 mg/ml.

20. The method of claim 1, further comprising the step of disrupting adhesions present at the location prior to administering the first and second hydrogel precursors.

21. The method of claim 1, wherein the method comprises administering a biologically active agent in solution with a hydrogel precursor or in a separate solution.

22. The method of claim 21, wherein the biologically active agent is a therapeutic agent selected from the group consisting of:

anti-infective agents, anti-inflammatory agents, anti-proliferative agents, anti-neoplastic agents, anti-oxidants, angiogenesis inhibitors, immunosuppressive agents, immunomodulatory agents, anti-coagulants, proteolytic agents, agents that enhance proteolysis, free radical scavengers, anti-oxidants, inhibitors of fibrous repair, and RNAi agents.

23. The method of claim 21, wherein the biologically active agent is an anti-inflammatory agent.

24. The method of claim 23, wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory agent.

25. The method of claim 24, wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of celecoxib, diclofenac, diflunisal, etodolac, salicylates, fenoprofen, ibuprofen, flurbiprofen, indomethacin, ketoprofen, ketorolac, meclofamate, meclofenamate, meloxicam, naproxen, piroxicam, sulindac, salsalate, nabumetone, aspirin, oxaprozin, and tolmetin.

26. The method of claim 23, wherein the anti-inflammatory agent is a steroidal anti-inflammatory agent.

27. The method of claim 26, wherein the steroidal anti-inflammatory agent is selected from the group consisting of dexamethasone, fluorometholone, prednisolone, loteprednol, medrysone, prednisone, methylpredisolone, budesonide, cortisone, rimexolone, clobetasol, halobetasol, hydrocortisone, triamcinolone, betamethasone, fluocinolone, and fluocinonide.

28. The method of claim 1, wherein the first and second hydrogel precursors are administered at a ratio between 1:

10 and 10;

1 by weight.

29. The method of claim 1, wherein at least one of the hydrogel precursors has a biologically active agent covalently attached thereto.

30. The method of claim 29, wherein the biologically active agent is a therapeutic agent selected from the group consisting of:

anti-infective agents, anti-inflammatory agents, anti-proliferative agents, anti-neoplastic agents, anti-oxidants, angiogenesis inhibitors, immunosuppressive agents, immunomodulatory agents, anti-coagulants, proteolytic agents, agents that enhance proteolysis, free radical scavengers, anti-oxidants, inhibitors of fibrous repair, and RNAi agents.

31. The method of claim 29, wherein the biologically active agent is an anti-inflammatory agent.

32. The method of claim 31, wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory agent.

33. The method of claim 32, wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of celecoxib, diclofenac, diflunisal, etodolac, salicylates, fenoprofen, ibuprofen, flurbiprofen, indomethacin, ketoprofen, ketorolac, meclofamate, meclofenamate, meloxicam, naproxen, piroxicam, sulindac, salsalate, nabumetone, aspirin, oxaprozin, and tolmetin.

34. The method of claim 31, wherein the anti-inflammatory agent is a steroidal anti-inflammatory agent.

35. The method of claim 34, wherein the steroidal anti-inflammatory agent is selected from the group consisting of dexamethasone, fluorometholone, prednisolone, loteprednol, medrysone, prednisone, methylpredisolone, budesonide, cortisone, rimexolone, clobetasol, halobetasol, hydrocortisone, triamcinolone, betamethasone, fluocinolone, and fluocinonide.

36. The method of claim 1, further comprising administering a plurality of particles together with the hydrogel precursors so that the particles become entrapped in a hydrogel formed by crosslinking of the hydrogel precursors.

37. The method of claim 36, wherein the particles are nanoparticles or microparticles that comprise a material selected from the group consisting of:

poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acids), poly(glycolic acids), poly(lactic acid-co-glycolic acids), polycaprolactone, polycarbonates, polyesteramides, poly(beta-amino esters), polyanhydrides, poly(amides), poly(amino acids), polyethylene glycol and derivatives thereof, polyorthoesters, polyacetals, polycyanoacrylates, polyetheresters, poly(dioxanones), poly(alkylene alkylates), copolymers of polyethylene glycol and polyorthoesters, biodegradable polyurethanes, and blends or copolymers of any of the foregoing polymers, and liposomes.

38. The method of claim 36, wherein the particles are present in a solution together with a hydrogel precursor prior to administration.

39. The method of claim 36, wherein the particles comprise a biologically active agent.

40. The method of claim 39, wherein the biologically active agent is a therapeutic agent selected from the group consisting of:

anti-infective agents, anti-inflammatory agents, anti-proliferative agents, anti-neoplastic agents, anti-oxidants, angiogenesis inhibitors, immunosuppressive agents, immunomodulatory agents, anti-coagulants, proteolytic agents, agents that enhance proteolysis, free radical scavengers, anti-oxidants, inhibitors of fibrous repair, and RNAi agents.

41. The method of claim 39, wherein the biologically active agent is an anti-inflammatory agent.

42. A composition comprising:

(a) a cellulose derivative;

(b) a dextran derivative; and

(c) a plurality of particles.

43. The composition of claim 42, wherein the particles are nanoparticles or microparticles that comprise a material selected from the group consisting of:

poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acids), poly(glycolic acids), poly(lactic acid-co-glycolic acids), polycaprolactone, polycarbonates, polyesteramides, poly(beta-amino esters), polyanhydrides, poly(amides), poly(amino acids), polyethylene glycol and derivatives thereof, polyorthoesters, polyacetals, polycyanoacrylates, polyetheresters, poly(dioxanones), poly(alkylene alkylates), copolymers of polyethylene glycol and polyorthoesters, biodegradable polyurethanes, and blends or copolymers of any of the foregoing polymers, and liposomes.

44. The composition of claim 42, wherein the particles are biodegradable.

45. The composition of claim 42, wherein the particles comprise a biologically active agent.

46. The composition of claim 45, wherein the biologically active agent is a therapeutic agent selected from the group consisting of:

anti-infective agents, anti-inflammatory agents, anti-proliferative agents, anti-neoplastic agents, anti-oxidants, angiogenesis inhibitors, immunosuppressive agents, immunomodulatory agents, anti-coagulants, proteolytic agents, agents that enhance proteolysis, free radical scavengers, anti-oxidants, inhibitors of fibrous repair, and RNAi agents.

47. The composition of claim 45, wherein the biologically active agent is an anti-inflammatory agent.

48. The composition of claim 42, wherein the composition is a hydrogel in which the cellulose derivative and the dextran derivative are crosslinked to one another.

49. The composition of claim 42 wherein the cellulose derivative or the dextran derivative has a biologically active agent covalently attached thereto.

50. The composition of claim 49, wherein the biologically active agent is a therapeutic agent selected from the group consisting of:

anti-infective agents, anti-inflammatory agents, anti-proliferative agents, anti-neoplastic agents, anti-oxidants, angiogenesis inhibitors, immunosuppressive agents, immunomodulatory agents, anti-coagulants, proteolytic agents, agents that enhance proteolysis, free radical scavengers, anti-oxidants, inhibitors of fibrous repair, and RNAi agents.

51. A method of administering particles to a location within the body comprising:

administering a composition comprising particles, a first hydrogel precursor, and a second hydrogel precursor, to the location,

wherein the first hydrogel precursor is a cellulose derivative or a dextran derivative;

wherein the second hydrogel precursor is a dextran derivative; and

wherein the first and second hydrogel precursors form a hydrogel that entraps the particles therein following administration.

52. The method of claim 51, wherein the composition is administered as one or more solutions at least one of which contains particles.

53. The method of claim 51, wherein the particles comprise a biologically active agent.

54. The method of claim 51, wherein the particles are nanoparticles or microparticles that comprise a material selected from the group consisting of:

poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acids), poly(glycolic acids), poly(lactic acid-co-glycolic acids), polycaprolactone, polycarbonates, polyesteramides, poly(beta-amino estera), polyanhydrides, poly(amides), poly(amino acids), polyethylene glycol and derivatives thereof, polyorthoesters, polyacetals, polycyanoacrylates, polyetheresters, poly(dioxanones), poly(alkylene alkylates), copolymers of polyethylene glycol and polyorthoesters, biodegradable polyurethanes, and blends or copolymers of any of the foregoing polymers, and liposomes.

55. A method of administering a biologically active agent to a subject comprising steps of:

administering a composition comprising a biologically active agent, a first hydrogel precursor, and a second hydrogel precursor to the location,

wherein the first hydrogel precursor is a cellulose derivative or a dextran derivative;

wherein the second hydrogel precursor is a dextran derivative; and

wherein the first and second hydrogel precursors form a hydrogel that entraps the biologically active agent therein.

56. The method of claim 55, wherein the biologically active agent is covalently attached to a hydrogel precursor.

57. The method of claim 55, wherein the biologically active agent is a therapeutic agent selected from the group consisting of:

anti-infective agents, anti-inflammatory agents, anti-proliferative agents, anti-neoplastic agents, anti-oxidants, angiogenesis inhibitors, immunosuppressive agents, immunomodulatory agents, anti-coagulants, proteolytic agents, agents that enhance proteolysis, free radical scavengers, anti-oxidants, inhibitors of fibrous repair, and RNAi agents.

58. The method of claim 55, wherein the biologically active agent is an anti-inflammatory agent.

59. The method of claim 55, wherein the biologically active agent is physically associated with particles.

60. The method of claim 55, wherein the biologically active agent is physically associated with nanoparticles or microparticles that comprise poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acids), poly(glycolic acids), poly(lactic acid-co-glycolic acids), polycaprolactone, polycarbonates, polyesteramides, poly(beta-amino esters), polyanhydrides, poly(amides), poly(amino acids), polyethylene glycol and derivatives thereof, polyorthoesters, polyacetals, polycyanoacrylates, polyetheresters, poly(dioxanones), poly(alkylene alkylates), copolymers of polyethylene glycol and polyorthoesters, biodegradable polyurethanes, and blends or copolymers of any of the foregoing polymers, and liposomes.